Roche Holding AG (HAM:RHO) Stock Price, Trades & News

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.47
Equity-to-Asset	0.34
Debt-to-Equity	0.98
Debt-to-EBITDA	1.53
Interest Coverage	13.73
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.6	Distress Grey Safe
Beneish M-Score	-2.7	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-1.1
	3-Year EBITDA Growth Rate	1.5
	3-Year EPS without NRI Growth Rate	-1.4
	3-Year FCF Growth Rate	-0.2
	3-Year Book Growth Rate	6.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	6.54
	Future 3-5Y Total Revenue Growth Rate Estimate	3.9

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	67.25
	9-Day RSI	61.25
	14-Day RSI	57.63
	3-1 Month Momentum %	4.84
	6-1 Month Momentum %	1.83
	12-1 Month Momentum %	25.41

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.38
	Quick Ratio	1.12
	Cash Ratio	0.55
	Days Inventory	165.79
	Days Sales Outstanding	69.74
	Days Payable	93.07

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.94
	Dividend Payout Ratio	0.5
	3-Year Dividend Growth Rate	1.4
	Forward Dividend Yield %	2.94
	5-Year Yield-on-Cost %	3.18
	3-Year Average Share Buyback Ratio	0.1
	Shareholder Yield %	4.14

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	73.73
	Operating Margin %	29.16
	Net Margin %	20.33
	EBITDA Margin %	34.26
	FCF Margin %	20.66
	OCF Margin %	29.77
	ROE %	41
	ROA %	13
	ROIC %	18.7
	3-Year ROIIC %	7.28
	ROC (Joel Greenblatt) %	76.11
	ROCE %	25.6
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	7

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	20.95
	Forward PE Ratio	16.99
	PE Ratio without NRI	17.27
	Shiller PE Ratio	23.41
	Price-to-Owner-Earnings	19.75
	PS Ratio	4.26
	PB Ratio	7.91
	Price-to-Tangible-Book	38.28
	Price-to-Free-Cash-Flow	20.64
	Price-to-Operating-Cash-Flow	14.31
	EV-to-EBIT	15.82
	EV-to-Forward-EBIT	12.93
	EV-to-EBITDA	13.35
	EV-to-Forward-EBITDA	11.35
	EV-to-Revenue	4.57
	EV-to-Forward-Revenue	4.46
	EV-to-FCF	22.16
	Price-to-GF-Value	1.27
	Price-to-Projected-FCF	1.67
	Price-to-Median-PS-Value	1.03
	Price-to-Graham-Number	5.42
	Earnings Yield (Greenblatt) %	6.32
	FCF Yield %	4.88
	Forward Rate of Return (Yacktman) %	2.87

GF Value™: €290.69

HAM:RHO

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with RHO. Try a 7-Day Free Trial to check it out.

Roche Holding AG Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Roche Holding AG Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings conference call for 2026	2026-07-24 14:00	In 26 days
Second quarter earnings results for 2026	2026-07-24 07:00	In 26 days
Roche’s Virtual ADA Investor Event	2026-06-08 17:00	362.00 (+0.22%)
CHF 0.999000 Cash Dividend	2026-03-12	373.80 (-1.84%)
CHF 9.800000 Cash Dividend	2026-03-12	373.80 (-1.84%)
General meeting for 2026	2026-03-10 10:30	378.00 (+1.61%)
Fourth quarter earnings conference call for 2025	2026-01-29 13:30	375.00 (-4.19%)
Fourth quarter earnings results for 2025	2026-01-29 07:00	375.00 (-4.19%)
Annual report for 2025	2026-01-28	390.60 (+1.67%)
Second quarter earnings conference call for 2025	2025-07-24 14:00	296.40 (+1.86%)

Show

Entries

Press Release

	Subject	Date
	Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies	2026-06-11
	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	2026-06-04
	/C O R R E C T I O N -- Roche/	2026-03-24
	Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets	2026-03-24
	Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation	2026-03-18
	Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease	2026-03-16
	New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools	2026-03-05
	Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities	2025-12-16
	Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche	2025-11-12
	Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test	2025-09-18

10/Page

Articles on Roche Holding AG

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Roche Holding AG - Bearer Shares

Business Description